Syon Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$151K Buy
36,456
+3,057
+9% +$10.4K 0.01% 1065
2026
Q2
$123K Buy
33,399
+22,429
+204% +$74.7K 0.01% 938
2026
Q1
$33.7K Buy
+10,970
New +$42.4K ﹤0.01% 904
2025
Q2
– Sell
-22,150
Closed -$117K – 777
2025
Q1
$117K Sell
22,150
-1,306
-6% -$9.5K 0.01% 569
2024
Q4
$159K Buy
+23,456
New +$158K 0.01% 535

Other funds holding RXRX

Syon Capital's RXRX Position: Q3 2026 in Review

Syon Capital increased its Recursion Pharmaceuticals (RXRX) stake by 9.2% in Q3 2026, buying an estimated $10.4K and bringing the position to 36,456 shares worth $151K. The position accounts for 0.01% of the portfolio, ranked #1065.

Syon Capital first reported a position in RXRX in Q4 2024 and has held it in 5 quarters since. The position peaked at $159K in Q4 2024. 352 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Syon Capital held 36,456 shares of Recursion Pharmaceuticals worth $151K as of Q3 2026.
  • Syon Capital bought 3,057 Recursion Pharmaceuticals shares in Q3 2026, an estimated $10.4K.
  • Recursion Pharmaceuticals made up 0.01% of Syon Capital's portfolio in Q3 2026, its #1065 holding.
  • Syon Capital first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Syon Capital's Recursion Pharmaceuticals position peaked at $159K in Q4 2024.
  • 352 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Syon Capital's 13F filing for Q3 2026, filed 16 Nov 2026.